M16-300: A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination with Nivolumab or Nivolumab and Ipilimumab for Adults with Extensive-Stage Small Cell Lung Cancer
To assess the safety of rovalpituzumab tesirine when given in combination with nivolumab or nivolumab and ipilimumab in people with extensive-stage small cell lung cancer (SCLC)
Small cell lung cancer (SCLC)
1. Confirmed diagnosis of extensive-stage small cell lung cancer (SCLC).
2. Must have had your disease worsen after at least one platinum-based chemotherapy.
3. Must have sufficient performance status and bone marrow function.
Other inclusion criteria may apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Subjects will receive study treatment for as long as their cancer is not getting worse and they do not have any significant side effects.
Knight Clinical Trials Information Line